BBIO vs. MDGL, OGN, NUVL, ALKS, PRGO, BPMC, BHVN, RARE, INSM, and IONS
Should you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include Madrigal Pharmaceuticals (MDGL), Organon & Co. (OGN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), Blueprint Medicines (BPMC), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), and Ionis Pharmaceuticals (IONS). These companies are all part of the "pharmaceutical preparations" industry.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
Madrigal Pharmaceuticals presently has a consensus price target of $377.40, suggesting a potential upside of 69.80%. BridgeBio Pharma has a consensus price target of $47.17, suggesting a potential upside of 89.04%. Given Madrigal Pharmaceuticals' higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Madrigal Pharmaceuticals.
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 28.5% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 5 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.94 beat Madrigal Pharmaceuticals' score of 0.48 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.
Madrigal Pharmaceuticals has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Madrigal Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
Madrigal Pharmaceuticals received 309 more outperform votes than BridgeBio Pharma when rated by MarketBeat users. Likewise, 68.66% of users gave Madrigal Pharmaceuticals an outperform vote while only 67.32% of users gave BridgeBio Pharma an outperform vote.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -6,913.92%. Madrigal Pharmaceuticals' return on equity of 0.00% beat BridgeBio Pharma's return on equity.
Summary
Madrigal Pharmaceuticals and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.
Get BridgeBio Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BridgeBio Pharma Competitors List
Related Companies and Tools
